Next Science Limited (NXS.AX)
Next Science Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.14, up 0.00% on the session, giving a market capitalisation of $42.4M. Its beta of 1.22 implies it has historically moved more than the broad market.
Next Science Limited operates as an innovative medical technology company, committed to researching, developing, and commercializing advanced solutions that combat the detrimental effects of biofilms on human health in both the United States and Australia. The firm's product development is underpinned by its proprietary Xbio Technology platform. Its diverse portfolio includes SURGX, an antimicrobial gel designed for managing surgical infections; BACTISURE, a specialized wound lavage formulated to eliminate biofilm; BlastX, an antimicrobial wound gel that not only eradicates bacteria but also guards against recolonization, all while sustaining a moist healing environment; and XPERIENCE, a convenient, no-rinse antimicrobial solution aimed at preventing surgical site infections. Established in 2012, Next Science Limited is headquartered in Chatswood, Australia.
Next Science Limited is most often compared with the following Healthcare names: